二甲双胍处方状态与美国退伍军人腹主动脉瘤疾病进展
在美国退伍军人事务医疗系统2003至2013年管理的无症状腹主动脉瘤且合并糖尿病患者中,共纳入13834例、58833份影像记录,比较二甲双胍处方与否的腹主动脉瘤年增长速率。二甲双胍处方与腹主动脉瘤年增长速率降低相关,作者认为这些发现支持开展前瞻性临床试验以检验二甲双胍限制早期腹主动脉瘤进展的能力。
要点
- 二甲双胍处方与腹主动脉瘤年增长速率降低相关,未校正均值1.2±1.9 mm/y vs 1.5±2.2 mm/y(P<.001),降低20%。
- 校正后二甲双胍处方与年增长速率降低相关:模型1为-0.23 mm(95%CI -0.35至-0.16;P<.001),模型2为0.20 mm/y(95%CI -0.26至-0.14;P<.001)。
- 基线瘤径35至49 mm亚组(7462例)显示相似抑制效应(1.4±2.0 mm/y至1.7±2.2 mm/y;P<.001)。
核心结论
- 在全国性退伍军人事务系统糖尿病患者分析中,二甲双胍处方与腹主动脉瘤扩大减少相关。
- 作者认为这些发现进一步支持开展前瞻性临床试验以检验二甲双胍限制早期腹主动脉瘤疾病进展的能力。
研究设计与样本
- 通过国际疾病分类第九版编码识别2003至2013年间在退伍军人事务医疗系统管理的所有无症状腹主动脉瘤患者。
- 纳入同时诊断为糖尿病且接受两次或以上腹部影像学检查(计算机断层扫描、磁共振成像或超声)记录腹主动脉瘤存在和大小、间隔至少1年的患者进行回顾。
- 最大腹主动脉瘤直径从放射学报告中确定,腹主动脉瘤手术修复后数据采集截尾。
- 查询合并症、当前吸烟状态及门诊药物记录(腹主动脉瘤诊断6个月内)。
- 采用两种统计模型比较按二甲双胍治疗状态分层的年腹主动脉瘤扩大速率(毫米/年):多变量线性回归(模型1)和多变量混合效应模型(模型2,含随机截距和随机斜率)。
主要发现
- 患者腹主动脉瘤诊断时平均年龄69.8±7.8岁,39.7%在腹主动脉瘤诊断±6个月内有二甲双胍处方。
- 整个队列腹主动脉瘤平均增长速率:模型1分析为1.4±2.0 mm/y,模型2分析为1.3±1.6 mm/y。
- 未校正的腹主动脉瘤平均增长速率:有二甲双胍处方患者为1.2±1.9 mm/y,无二甲双胍处方患者为1.5±2.2 mm/y(P<.001),降低20%。
- 校正腹主动脉瘤进展相关变量后,二甲双胍处方与年腹主动脉瘤增长速率降低相关:模型1分析为-0.23 mm(95%CI -0.35至-0.16;P<.001),模型2分析为0.20 mm/y(95%CI -0.26至-0.14;P<.001)。
- 基线腹主动脉瘤大小35至49 mm的7462例患者亚组分析显示相似抑制效应(1.4±2.0 mm/y至1.7±2.2 mm/y;P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identification of a safe and effective medical therapy for abdominal aortic aneurysm (AAA) disease remains a significant unmet medical need. Recent small cohort studies indicate that metformin, the world's most commonly prescribed oral hypoglycemic agent, may limit AAA enlargement. We sought to validate these preliminary observations in a larger cohort. METHODS: All patients with asymptomatic AAA disease managed in the Veterans Affairs Health Care System between 2003 and 2013 were identified by International Classification of Diseases, Ninth Revision codes. Those with a concomitant diagnosis of diabetes mellitus who also received two or more abdominal imaging studies (computed tomography, magnetic resonance imaging, or ultrasound) documenting the presence and size of an AAA, separated by at least 1 year, were included for review. Maximal AAA diameters were determined from radiologic reports. Further data acquisition was censored after surgical AAA repair, when performed. Comorbidities, active smoking status, and outpatient medication records (within 6 months of AAA diagnosis) were also queried. Yearly AAA enlargement rates, as a function of metformin treatment status, were compared using two statistical models expressed in millimeters per year: a multivariate linear regression (model 1) and a multivariate mixed-effects model with random intercept and random slope (model 2). RESULTS: A total of 13,834 patients with 58,833 radiographic records were included in the analysis, with radiology imaging follow-up of 4.2 ± 2.6 years (mean ± standard deviation). The average age of the patients at AAA diagnosis was 69.8 ± 7.8 years, and 39.7% had a metformin prescription within ±6 months of AAA. The mean growth rate for AAAs in the entire cohort was 1.4 ± 2.0 mm/y by model 1 analysis and 1.3 ± 1.6 mm/y by model 2 analysis. The unadjusted mean rate of AAA growth was 1.2 ± 1.9 mm/y for patients prescribed metformin compared with 1.5 ± 2.2 mm/y for those without (P < .001), a 20% decrease. This effect remained significant when adjusted for variables relevant on AAA progression: metformin prescription was associated with a reduction in yearly AAA growth rate of -0.23 mm (95% confidence interval, -0.35 to -0.16; P < .001) by model 1 analysis and 0.20 mm/y (95% confidence interval, -0.26 to -0.14; P < .001) by model 2 analysis. A subset analysis of 7462 patients with baseline AAA size of 35 to 49 mm showed a similar inhibitory effect (1.4 ± 2.0 mm/y to 1.7 ± 2.2 mm/y; P < .001). Patients' factors associated with an increased yearly AAA growth rate were baseline AAA size, metastatic solid tumors, active smoking, chronic obstructive pulmonary disease, and chronic renal disease. Factors associated with decreased yearly AAA growth rates included prescriptions for angiotensin II type 1 receptor blockers or sulfonylureas and the presence of diabetes-related complications. CONCLUSIONS: In a nationwide analysis of diabetic Veterans Affairs patients, prescription for metformin was associated with decreased AAA enlargement. These findings provide further support for the conduct of prospective clinical trials to test the ability of metformin to limit progression of early AAA disease.
引用
- Itoga NK, Rothenberg KA, Suarez P, et al. Metformin prescription status and abdominal aortic aneurysm disease progression in the U.S. veteran population. J Vasc Surg. 2018. PMID: 30197158. doi:10.1016/j.jvs.2018.06.194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。